WS #14773
The biotech sector is buoyed by positive clinical data from Legend Biotech and Johnson & Johnson, which reported that 50% of patients remained progression-free at five years following a single CARVYKTI infusion for multiple myeloma. This long-term efficacy data reinforces the drug's value proposition. In legal news, Nektar Therapeutics was awarded $90 million in damages by a jury finding that Eli Lilly breached its license agreement, providing a direct financial boost to Nektar. Nike (NKE) faces significant headwinds as Bank of America downgraded the stock to 'Underperform' and slashed its price target from $47 to $30. The firm cited a lack of innovation overshadowing pressure on Nike's core business, with forecasts for sales declines extending into fiscal year 2027. This downgrade highlights broader concerns about consumer discretionary spending and the challenges legacy athletic brands face in a competitive market.
Healthcare and Biotech Developments
The biotech sector is buoyed by positive clinical data from Legend Biotech and Johnson & Johnson, which reported that 50% of patients remained progression-free at five years following a single CARVYKTI infusion for multiple myeloma. This long-term efficacy data reinforces the drug's value proposition. In legal news, Nektar Therapeutics was awarded $90 million in damages by a jury finding that Eli Lilly breached its license agreement, providing a direct financial boost to Nektar.
Nike (NKE) faces significant headwinds as Bank of America downgraded the stock to 'Underperform' and slashed its price target from $47 to $30. The firm cited a lack of innovation overshadowing pressure on Nike's core business, with forecasts for sales declines extending into fiscal year 2027. This downgrade highlights broader concerns about consumer discretionary spending and the challenges legacy athletic brands face in a competitive market.